Karyopharm announces phase 3 siendo study meets primary endpoint with statistically significant increase in progression-free survival in patients with advanced or recurrent endometrial cancer

Newton, mass., feb. 8, 2022 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced positive top-line results from the phase 3 s elinexor i n endo metrial cancer (siendo/engot-en5/gog-3055) study (n=263) evaluating the efficacy and safety of front-line maintenance therapy using selinexor, an oral medication, in patients with advanced or recurrent endometrial cancer.
KPTI Ratings Summary
KPTI Quant Ranking